IIM
BMRN icon

Ivory Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ivory Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-62,173
Closed -$5.75M – 57
2016
Q3 		$5.75M Buy
+62,173
New +$5.85M 0.16% 75

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ivory Investment Management's BMRN Position: Q4 2016 in Review

Ivory Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2016, closing a stake of 62,173 shares — an estimated $5.75M sold.

Ivory Investment Management first reported a position in BMRN in Q3 2016 and held it in 1 quarter. The position peaked at $5.75M in Q3 2016. 414 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

  • Ivory Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Ivory Investment Management sold 62,173 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $5.75M.
  • Ivory Investment Management first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Ivory Investment Management's BioMarin Pharmaceuticals position peaked at $5.75M in Q3 2016.
  • 414 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on Ivory Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.